Merck, Inc.
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 520
- Registration Number
- NCT06305754
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital ( Site 3132), Hefei, Anhui, China
🇨🇳Beijing Peking Union Medical College Hospital-pneumology department ( Site 3107), Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Soochow University-Respiratory Department ( Site 3118), Suzhou, Jiangsu, China
A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 230
- Registration Number
- NCT06305767
- Locations
- 🇵🇪
Hospital Militar Central Luis Arias Schereiber ( Site 1700), Jesús María, Lima, Peru
🇵🇪Oncosalud ( Site 1701), Lima, Peru
🇨🇦Centre Hospitalier de l'Université de Montréal ( Site 0005), Montréal, Quebec, Canada
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 272
- Registration Number
- NCT06307431
- Locations
- 🇫🇷
Gustave Roussy ( Site 0304), Villejuif, Ile-de-France, France
🇫🇷Hôpital Européen Georges Pompidou ( Site 0300), Paris, France
🇩🇪Klinikum Stuttgart - Katharinenhospital ( Site 0400), Stuttgart, Baden-Wurttemberg, Germany
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06295796
- Locations
- 🇺🇸
Research by Design ( Site 0001), Chicago, Illinois, United States
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 42
- Registration Number
- NCT06294912
- Locations
- 🇦🇺
USC Clinical Trials Brisbane (South Bank) ( Site 0001), South Brisbane, South Australia, Australia
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
- Conditions
- Interventions
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1012
- Registration Number
- NCT06295809
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian ( Site 1122), Newport Beach, California, United States
🇧🇷Clinica Amo - Rio Vermelho-INSTITUTO ETICA ( Site 1315), Salvador, Bahia, Brazil
🇧🇷Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site, São José do Rio Preto, Sao Paulo, Brazil
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06285240
- Locations
- 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida, United States
🇺🇸CenExel iResearch, LLC ( Site 0003), Decatur, Georgia, United States
🇺🇸CenExel iResearch, LLC ( Site 0004), Savannah, Georgia, United States
A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06273774
- Locations
- 🇺🇸
Woodland International Research Group-Clinical Research ( Site 0009), Little Rock, Arkansas, United States
🇺🇸Hassman Research Institute Marlton Site ( Site 0006), Marlton, New Jersey, United States
🇺🇸Atlanta Center for Medical Research ( Site 0001), Atlanta, Georgia, United States
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 304
- Registration Number
- NCT06242691
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics (START) ( Site 0005), San Antonio, Texas, United States
🇺🇸University of Virginia Health System-Hematology-Oncology ( Site 0009), Charlottesville, Virginia, United States
🇮🇱Rambam Health Care Campus-Oncology Division ( Site 0602), Haifa, Israel
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 378
- Registration Number
- NCT06212752
- Locations
- 🇯🇵
Miyagi Cancer Center ( Site 4401), Natori, Miyagi, Japan
🇯🇵Fujita Health University ( Site 4406), Toyoake, Aichi, Japan
🇯🇵Kurume University Hospital ( Site 4412), Kurume, Fukuoka, Japan